Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study
* The world's first non-surgical cervical HSIL treatment validated by an international Phase III clinical study with proven efficacy; * The response rate increased by 89.4% compared to the placebo control group, with a low incidence of adverse events; * The China new drug application submiss...
Asieris Releases Phase III Clinical Study and Real-World Research Data for APL-1706, a Bladder Cancer Diagnosis and Management Drug, at the 2024 ASCO-GU
SHANGHAI, Jan. 29, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the release of ...
Asieris Presents for the First Time Interim Analysis Data of Oral APL-1202 in Combination with PD-1 Inhibitor Tislelizumab for Neoadjuvant Treatment of Muscle-Invasive Bladder Cancer at 2024 ASCO-GU
SHANGHAI, Jan. 29, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the first-time ...
Asieris will Present For the First Time Interim Analysis Data of Oral APL-1202 in Combination with PD-1 Inhibitor Tislelizumab for Neoadjuvant Treatment of Muscle-Invasive Bladder Cancer at 2024 ASCO-GU
SHANGHAI, Jan. 25, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the interi...
Enhancing Leadership in Gynecology, Asieris Pharmaceuticals Appoints Sophia Cao to Lead the Newly-Established Women's Health Business Unit, Accelerating Strategic Expansion
SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock code ：688176.SH) has announced its set-up of the Women's Health Business Unit for commercialization. This strategic move is designed to enhance the company's focus on genitourinary diseases and strengthen its position in women'...
APL-2301, a compound developed by Asieris for the treatment of Acinetobacter baumannii infection, was approved for Phase I clinical trials in Australia
SHANGHAI, Dec. 24, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that its product, APL-23...
Asieris Unveiled Results of Its Phase III Clinical Study for APL-1706, an Imaging Drug for Diagnosis or Surgery of Bladder Cancer, at the SIU 2023 Congress
SHANGHAI, Oct. 12, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, has unveiled its phase III clinica...
The First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint
SHANGHAI, Sept. 20, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, has announced that the multinatio...
Asieris' New Drug APL-1401 Completes First Administration in Patient with Moderately to Severely Active UC
SHANGHAI, Sept. 14, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that its oral drug APL-1401 for the tr...
Asieris Announces Positive Interim Analysis Results in Phase II Clinical Trial of Oral APL-1202 in Combination with Tislelizumab, a PD-1 inhibitor, as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer
SHANGHAI, Sept. 13, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the clinical trial of oral APL-12...
Asieris Obtained IND Approval from NMPA for APL-1401, a Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis
SHANGHAI, Aug. 30, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the National Medical Products Adm...
Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization
SHANGHAI, Aug. 22, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH) – a global innovative pharmaceutical company specializing in the discovery, development and commercialization of innovative drugs that treat genitourinary (GU) tumors and other related diseases – today release...
Hong Kong Department of Health has Approved the Registration Applications for the Uro-G and Uro-V Disposable Cystoscopic System
SHANGHAI, Aug. 15, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the Government of Hong Kong Specia...
Asieris Announces Positive Phase III Bridging Trial of Hexvix®, a Diagnostic Drug for Bladder Cancer
SHANGHAI, Aug. 11, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the Phase III bridging clinical tr...
Hexvix®, A Diagnostic Drug for Bladder Cancer of Asieris has Completed the Phase III bridging trial Enrollment
SHANGHAI, July 6, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the completion of patient enrollment for...
Asieris' progress in MIBC receives renewed attention with its inclusion in ASCO 2023
SHANGHAI, May 31, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176)， a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the phase I clinical data of ANTICIPATE ...
Asieris Deepens Strategic Partnership with UroViu to Further Develop Integrated Diagnosis and Treatment Platform for Bladder Cancer
SHANGHAI, May 18, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced a strategic collaboration with UroViu C...
Asieris Releases 2022 Annual Report: Makes Steady Progress in its Clinical Development, Global Expansion to Treat Genitourinary Tumors, and Implementing its Commercialization Strategy to Provide Integrated Diagnosis-to-Treatment Solutions
SHANGHAI, April 17, 2023 /PRNewswire/ -- Asieris Pharmaceuticals(688176.SH), a global biopharma company specializing in the discovery, development and commercialization of innovative drugs that treat genitourinary (GU) tumors and other related diseases, today released its 2022 annual report. Whil...
Asieris' subsidiary makes significant progress in its commercialization strategy by obtaining the "Drug Distribution License"
SHANGHAI, April 10, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that its subsidiary, Hainan Yahong ph...
NMPA accepted the registration applications for Uro-G and Uro-3500
SHANGHAI, Feb. 21, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the registration applications for ...
